Radiotherapy, androgen deprivation timing and implications for prostate cancer treatment during COVID-19

What The Study Did: National Cancer Database data from 2004 to 2014 were used to examine the association between overall survival and timing of radiotherapy relative to androgen deprivation therapy in patients with prostate cancer.

Authors: Vinayak Muralidhar, M.D., M.Sc., of the Dana-Farber Cancer Institute/Brigham and Women’s Hospital and Harvard Medical School in Boston is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ 

(doi:10.1001/jamaoncol.2020.3545)

Editor’s Note: The article includes conflicts of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

###

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2020.3545?guestAccessKey=481a5a08-0acc-4fff-8baa-95f3acac0858&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=081320

Media Contact
JAMA Network Media Relations

[email protected]

Comments